Medizinische Universität Graz - Research portal
Selected Publication:
Ferenci, P; Brunner, H; Nachbaur, K; Datz, C; Gschwantler, M; Hofer, H; Stauber, R; Hackl, F; Jessner, W; Rosenbeiger, M; Munda-Steindl, P; Hegenbarth, K; Gangl, A; Vogel, W; Australian Hepatitis Study Group.
Combination of interferon induction therapy and ribavirin in chronic hepatitis C.
Hepatology. 2001; 34(5):1006-1011
Doi: 10.1053/jhep.2001.28706
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- Hegenbarth Karin
- Hofer Herwig
- Stauber Rudolf
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The initial clearance of hepatitis C virus (HCV) during interferon-alfa therapy is dose-dependent. Therefore, higher initial interferon doses (induction therapy) may improve treatment results. This concept was tested in a prospective, randomized controlled trial. Previously untreated patients with chronic hepatitis C were randomized to receive 3 different interferon doses during the first 14 weeks of therapy (Group A, n = 130: 10 MU IntronA [AESCA-Schering Plough, Traiskirchen, Austria]/day for 2 weeks, followed by 10 MU/2 days for 12 weeks; Group B, n = 124: 5 MU/day for 14 weeks; Group C, n = 119; 5 MU/2 days for 14 weeks) followed in all by 5 MU/2 days for 24 weeks. Throughout the whole study all patients received 1 to 1.2 g ribavirin/day. On treatment, no differences in viral clearance rates were observed. Sustained response rates were also not different among the groups (A: 48.5%, B and C: 41.3%, intent to treat). When data were analyzed according to genotypes, sustained response was almost twice as high in patients with genotype 1 receiving high-dose interferon induction therapy (A: 44.2%, B: 28.6%, C: 27%, P <.05). In contrast, results were not different in genotype 3a patients (A: 61.3%, B: 75.9%, C: 56.3%; P >.1). These data indicate that high-dose interferon induction therapy may improve the outcome of interferon/ribavirin combination therapy in genotype 1 patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antiviral Agents - adverse effects
- Drug Therapy, Combination - adverse effects
- Female - adverse effects
- Hepatitis C, Chronic - drug therapy
- Humans - drug therapy
- Interferon Inducers - adverse effects
- Male - adverse effects
- Middle Aged - adverse effects
- Patient Dropouts - adverse effects
- Prospective Studies - adverse effects
- Ribavirin - adverse effects
- Treatment Outcome - adverse effects
- Viral Load - adverse effects